WO2005079826A1 - 疲労回復剤及び疲労回復用食品 - Google Patents
疲労回復剤及び疲労回復用食品 Download PDFInfo
- Publication number
- WO2005079826A1 WO2005079826A1 PCT/JP2005/001752 JP2005001752W WO2005079826A1 WO 2005079826 A1 WO2005079826 A1 WO 2005079826A1 JP 2005001752 W JP2005001752 W JP 2005001752W WO 2005079826 A1 WO2005079826 A1 WO 2005079826A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- peptide
- fatigue
- food
- gsp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/346—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/347—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of proteins from microorganisms or unicellular algae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a fatigue recovery agent and a food for fatigue recovery, which are used by those who feel tired in daily life, exhausted by intense or prolonged exercise or work, or feel uncertain complaints when getting up. Things.
- dipeptides such as anserine and carnosine also have a recovery effect from fatigue.
- peptides obtained by enzymatic decomposition have a strong bitter taste, and thus have some functional problems.
- Patent Document 1 Japanese Patent Publication No. 5-505524
- Patent Document 2 JP-A-8-264
- Patent Document 3 JP-A-9-121870
- Patent document 4 JP-A-2000-83695
- Patent Document 5 US Patent No. 4266031
- Non-patent document 1 “Molecular Cloning: A Laboratory Manual”, Cold Spring Harbor, 1982, p. 4 Disclosure of the invention
- the body becomes tired after performing work requiring exercise or physical strength, or when waking up early in the morning, and also recovers physical strength in a state where the spontaneous movement is reduced (a state where the amount of spontaneous exercise is reduced).
- An object of the present invention is to provide a fatigue recovery agent and a food for recovery from fatigue that can prevent the deterioration of physical strength and maintain physical strength.
- the present inventors have conducted intensive studies in order to achieve the above-mentioned object, and as a result, have found that a proteolytic peptide obtained by degrading a protein with a thiol protease derived from germinated soybean cotyledons and a serine protease derived from a microorganism or Z or a microorganism. Have excellent fatigue recovery effect and nourishing tonic effect, and have completed the present invention.
- the present invention includes the following inventions.
- a rejuvenating or nourishing tonic comprising a proteolytic peptide obtained by decomposing a protein-containing material with a thiol protease derived from germinated soybean cotyledons and a serine protease derived from Z or a microorganism.
- the protein-containing raw material power The fatigue-relieving or nourishing tonic according to the above (1), which is selected from the group consisting of casein, wheat protein, and bonito.
- the protein-containing raw material power The food for recovering fatigue or nourishing tonics according to (3), which is selected from the group consisting of casein, wheat protein, and bonito.
- the present invention provides a fatigue recovery agent and a food for recovery from fatigue that are excellent in a fatigue recovery effect and a nourishing tonic effect. Further, since the fatigue recovery agent and the food for recovery from fatigue according to the present invention have no sensory problems such as bitterness, they can be easily taken.
- FIG. 1 shows the results of Example 1.
- FIG. 2 is a view showing a result (change in spontaneous movement) of Example 2.
- FIG. 3 is a graph showing the results (changes in spontaneous movement) of Example 3.
- FIG. 4 is a view showing a result (change in spontaneous exercise amount) of Example 4.
- FIG. 5 is a view showing a result (change in spontaneous movement) of Example 5.
- the proteolytic peptide used in the present invention is obtained by decomposing a protein-containing material with thiol protease and Z derived from germinated soybean cotyledons or serine protease derived from a microorganism.
- the thiol protease derived from germinated soybean cotyledons (hereinafter, also referred to as "D3") used in the present invention is known, and is derived from germinated soybean cotyledons and converts soybean seed storage proteins to amino acids or low molecular weight peptides. It is a proteolytic enzyme that can be degraded and is known to have the following properties:
- activator activated with 2-mercaptoethanol, cysteine, reduced daltathione
- the method of separating and purifying D3 from germinated soybean cotyledons can be carried out by a known method, which is described in detail in, for example, JP-A-8-264.
- D3 used in the present invention it is of course possible to use D3 produced by a transformant obtained by genetic recombination using only D3 obtained directly from germinated soybean cotyledons.
- Methods for producing D3 using transformants are known.
- DNA encoding D3 is incorporated into an appropriate expression vector, and this expression vector is introduced into a microorganism or cell such as E. coli yeast to transform D3.
- a transformant to be produced can be obtained.
- the method for producing such a recombinant D3 is described in detail, for example, in JP-A-09-121870, "DNA encoding a novel thiol protease and a method for producing the thiol protease using the same".
- D3-Q There are two types of isozymes (D3-Q; and D3-j8) in D3, both of which can be used.
- the amino acid sequences of D3- ⁇ and D3-j8 are shown in SEQ ID NOs: 1 and 2.
- D3 that can be used in the present invention, not only those having the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, but also derivatives thereof can be used.
- the ⁇ derivative '' of D3 refers to one or more amino acids in the natural amino acid sequence by adding one or more amino acids to the C-terminal and Z- or N-terminal of the natural amino acid sequence of natural protein D3. Substitution of one or more amino acids at different sites, deletion of one or more amino acids at either or both termini of the native protein or at one or more positions in the amino acid sequence, or The proteolytic activity of this enzyme is impaired by the insertion of one or more amino acids at one or more sites in the sequence, provided that the protein is derived from the native enzyme D3. It is understood to mean a degrading enzyme.
- GSP serine protease
- the serine protease is known and is a proteolytic enzyme that specifically cleaves the C-terminal side of glutamic acid (Glu) residue and the C-terminal side of aspartic acid (Asp) residue. It is known to have the following properties:
- microorganisms that produce serine protease as described above include microorganisms belonging to the genera Bacillus, Streptomyces, Staphylococcus, and Actinomyces. I can get lost. More specifically, for example, Bacillus' Riche-Hormis (Bacillus licheniformis), Bacillus' subtilis (Bacillus subtilis), Streptomyces' Streptomyces thermovulgaris, S Economics. DOO Seth 'glycerin 1 / scan (Streptomyces gnseus), Staph Gray Lactococcus. Aureusu (Staphylococcus aureus), and the like.
- the GSP used in the present invention can be isolated from a culture of the microorganism as described above by a well-known method, for example, the method described in US Pat. It can be purified.
- the GSP derived from a microorganism belonging to the genus Bacillus used in the present invention is a mutant of a microorganism belonging to the genus Bacillus, for example, a gene encoding a subtilisin A, for example, the aforementioned US Patent No. 4,266.
- Inactivated mutants may be obtained by conventional mutagenesis methods including the use of mutagens (eg, nitrosoguanidine) by the methods disclosed in US Pat.
- the GSP used in the present invention may be a GSP obtained by genetic recombination, that is, a DNA sequence encoding a GSP from a microorganism producing the enzyme, for example, a cDNA or a genomic library of Bacillus' lisii-formis. Isolating, inserting the DNA sequence into an appropriate expression vector, transforming the appropriate host microorganism with the vector, and growing the host under conditions that facilitate the production of the enzyme; GSP obtained by recovering the culture power GSP can also be used. These steps are performed by standard methods. T. Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold spring
- GSP that can be used in the present invention, not only those having the amino acid sequence shown in SEQ ID NO: 3 but also derivatives thereof can be used.
- a “derivative” of GSP refers to one or more different sites in the natural amino acid sequence by adding one or more amino acids to the C-terminal and Z- or N-terminal of the natural amino acid sequence of the natural protein GSP. Substitution of one or more amino acids of either or both ends of the native protein, or deletion of one or more amino acids at one or more sites in the amino acid sequence, or of one or more amino acids in the native amino acid sequence. Alternatively, the insertion of one or more amino acids at multiple sites results in the proteolytic activity of this enzyme. Sex is impaired by this and is understood to mean a proteolytic enzyme derived from the natural enzyme GSP.
- GSP is a mutant strain in which other proteases are inactivated, for example, a gene encoding subtilisin A in the case of a Bacillus scherichia-formis strain, for example, a mutant that is substantially inactivated.
- a fractionation method a deviation method such as fractionation by ammonium sulfate precipitation, fractionation by membrane treatment, and fractionation by ion exchange resin-gel filtration chromatography may be used.
- the presence of an enzyme other than the protease does not affect the properties of the proteolysate.
- the protein raw material used in the present invention is not particularly limited as long as it is a substance or a material containing a protein component.
- the protein component is whey protein, casein, meat protein, fish protein, erythrocyte, egg white, Animal protein such as collagen or gelatin, soy protein, wheat darten, zein, rapeseed protein, purple coconut palm protein, pea protein, legume protein, cottonseed protein, potato protein, rice protein or sesame seed protein, etc.
- protein proteins containing protein components such as cereal proteins.
- casein, wheat protein or bonito is particularly preferred as a protein material.
- proteolytic peptide used in the present invention can be prepared as follows.
- an aqueous protein solution having a concentration of about 11 to 10% by weight is prepared and, if necessary, heat-treated (for example, heated at 121 ° C for 15 minutes), and then the solution is adjusted to pH 3-6 with hydrochloric acid or sulfuric acid, preferably Adjust the pH to around 3.5-5.
- To this protein solution is added proteinase D3 in an amount of 0.05-2 g, preferably 0.1-lg, per 100 g of protein.
- the protein solution to which D3 has been added is subjected to an enzymatic reaction at 30 ° C. to 50 ° C.
- reaction solution was subjected to a heat treatment (for example, heat treatment at 80 ° C for 20 minutes) to inactivate the enzyme, and a supernatant fraction containing a proteolytic peptide was obtained by centrifugation. Neutralize the pH of the supernatant to around neutral with NaOH and freeze-dry. Upon drying, an enzymatically degraded peptide can be obtained.
- a heat treatment for example, heat treatment at 80 ° C for 20 minutes
- the monitoring and titration of the pH is performed automatically on the pH-stat.
- an aqueous protein solution having a concentration of about 110% by weight is prepared, and if necessary, heat-treated (for example, heated at 121 ° C for 15 minutes), The solution is treated with a base (eg, NaOH, KOH, NaHCO, etc.) to pH7-
- a base eg, NaOH, KOH, NaHCO, etc.
- the protein solution to which GSP has been added is subjected to an enzyme reaction at 30 ° C. to 50 ° C. (preferably 40 to 50 ° C.) for 1 to 48 hours, preferably 4 to 18 hours.
- the reaction solution was heated (eg, 80 ° C., 20 minutes) to inactivate the enzyme, and the supernatant fraction containing the proteolytic peptide was obtained by centrifugation.
- the pH in the supernatant can be neutralized to near neutrality, and the enzyme-degraded peptide can be obtained by freeze-drying.
- the protein material is enzymatically decomposed with D3 and Z or GSP to obtain a proteolytic peptide mixture.
- the enzymatic decomposition reaction is carried out so that the molecular weight range of the peptide obtained after the enzymatic decomposition is 150 to 20,000, preferably 500 to 5,000.
- the low-molecular-weight peptide component (molecular weight in the range of 150-20,000, preferably 500-5,000) in the proteolytic peptide mixture obtained after the enzymatic digestion accounts for at least 60% by weight of the total peptide mixture obtained. It is preferable to carry out the enzymatic decomposition reaction so that
- the fatigue recovery agent or nutrient tonic of the present invention contains the proteolytic peptide obtained as described above, and includes, for example, capsules, powders, tablets, It may be formulated into granules, fine granules, syrups, solutions, suspensions, rectal administration, injections, infusions and the like. These preparations follow general preparation methods in the field of pharmacology. Can be easily manufactured.
- the form of the food is not particularly limited, and examples thereof include powder, solid food, liquid food, beverage, and jelly.
- they may be in the form of dietary supplements such as so-called supplements.
- the nutritional supplements and foods of the present invention may contain, in addition to the proteolytic peptide, other nutrients and medicinal ingredients, and additives commonly used in the pharmaceutical and food fields.
- additional components and additives include, for example, amino acids, vitamins, carbohydrates, lipids, proteins, vitamins, minerals, caffeine or crude drugs, and additives include pigments, diluents, fragrances, preservatives, etc. Agents, excipients, disintegrants, lubricants, binders, surfactants, plasticizers, etc., preservatives, antioxidants and the like.
- the dosage (intake) of the nutritional supplement and food of the present invention will be described.
- the effect of recovering fatigue was observed when the dose exceeded lg / kg in dry weight.
- the amount of protein consumed per day by the mouse is about 0.9 g
- the minimum effective dose of proteolytic peptide is lg / kg.
- the intake is 0.025g.
- this ratio is multiplied by the required daily protein intake of 80 g for adults, the minimum effective dose is 2 gZ days or more for adults, but the minimum effective dose is weight, age, sex and fatigue. It changes depending on the degree and can be set appropriately.
- the required minimum daily amount may be ingested at one time, or may be divided into a plurality of times.
- the nutritional supplements and foods of the present invention have the effect of maintaining the health of healthy persons who are not tired and not deteriorating the fatigue in healthy persons who are not only tired but remarkably recovered when ingested during fatigue. Have.
- Reference Example 1 Method for Producing Enzymatically Degraded Peptide (Protein Hydrolysis Using Protease) 500 ml of a suspension containing casein, wheat protein or bonito flour (this suspension contains approximately 5% protein (NX6. 25) containing germinated soybean-derived protease D3 (0.5% of substrate by weight of protein) or GSP (1% of substrate by weight of protein).
- the enzymatic degradation reaction was performed at pH 4.5 and 40 ° C for D3 and at pH 8.0 and 45 ° C for GSP.
- the pH was kept constant by adding 4M HC1 or 4M NaOH.
- the pH was adjusted to near neutral, and the enzyme was inactivated by heat treatment at 80 ° C for 20 minutes. Further, insoluble substances were precipitated by centrifugation at 10,000 g for 5 minutes, and only the soluble fraction was freeze-dried and subjected to a fatigue recovery test.
- the protein degradation products of subtilisin and pepsin used for comparison were also prepared according to the above method, the amount of enzyme added was 0.5% of the substrate in terms of protein weight, the reaction time was 8 hours, and the reaction temperature was 8 hours. Performed an enzymatic degradation reaction at 40 ° C. The reaction pH was adjusted to pH 8.0 when subtilisin was used, and to pH 2.0 when pepsin was used.
- a group of 8-week-old male CDF-1 mice, each with 8 mice (n 8 in each group), were placed on a treadmill and subjected to forced walking for 3 hours, and then separated with germinated soybean cotyledon-derived protease D3. Then, (1) casein peptide and (2) wheat peptide were orally administered to each as a dry weight of lg / kg, and then the locomotor activity for 60 minutes was measured using a locomotor activity measuring device with an infrared sensor. Then, a comparison was made with a control group (control group; administration of only deionized distilled water). The results are shown in Figure 1.
- FIG. 2 shows the results. As shown in Fig. 2, germinated soybean cotyledon-derived protease
- D3-degraded casein peptide and serine protease (GSP) -degraded casein peptide showed a marked increase in locomotor activity.
- the group administered pepsin-degraded casein peptide and subtilisin-degraded casein peptide showed an increase in locomotor activity.
- Three groups of 5-week-old male CDF-1 mice were placed on a treadmill and subjected to forced walking exercise for 3 hours, after which (1) casein protein, (1) 2) Amino acid mixture (mixture of amino acids that make up casein protein: taurine, aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, parin, methionine, isopenic isine, leucine, tyrosine, fenylalanine , Lysine, histidine, anserine, carnosine, arginine) (3) Germinated soybean cotyledon-derived protease D3-degraded katsuba node peptide, (4) germinated soybean-cotyledon-derived protease D3-degraded casein peptide was orally administered by lg / kg. Then, the locomotor activity was measured for 60 minutes using a loco
- FIG. 3 shows the results. As shown in the figure, no effect was observed with the casein protein, whereas a spontaneous increase in locomotor activity was observed with the protease D3-degraded Katsuo node peptide derived from germinated soybean cotyledon and the protease D3-degraded casein peptide derived from germinated soybean cotyledon. .
- Two groups of 5-week-old male CDF-1 mice were placed on a treadmill and subjected to forced walking for 3 hours.
- germinated soybean cotyledon-derived protease D3-degraded casein peptide 2 (lg / kg as dose) followed by spontaneous irradiation with an infrared sensor Spontaneous locomotion for 60 minutes was measured using a locomotion measuring device, and compared with a control group (control group; administration of distilled water only).
- FIG. 4 shows the results. As can be seen from FIG. 4, degradation of protease D3 derived from germinated soybean cotyledons was most effective at a dose of 1 g / kg.
- FIG. 5 shows the results. As can be seen from FIG. 5, a remarkable increase in locomotor activity was observed even at a dose as low as 0.5 g / kg of the GSP-degraded casein peptide.
- the nutritional supplements and foods of the present invention can be used for preventing fatigue or health in healthy individuals who can not only be used as a fatigue recovery agent or a food for recovering fatigue from the state of fatigue and health immediately. It is useful as a tonic or tonic food to maintain the condition.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/589,073 US20080009440A1 (en) | 2004-02-24 | 2005-02-07 | Soothing Agent and Food for Treating Fatigue |
EP05709804A EP1721616B1 (en) | 2004-02-24 | 2005-02-07 | Protein hydrolysate for treating fatigue |
DE602005013650T DE602005013650D1 (de) | 2004-02-24 | 2005-02-07 | Proteinhydrolysat zur behandlung von müdigkeit |
US12/339,790 US20090203604A1 (en) | 2004-02-24 | 2008-12-19 | Soothing agent and food for treating fatigue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004048417A JP2005239579A (ja) | 2004-02-24 | 2004-02-24 | 疲労回復剤及び疲労回復用食品 |
JP2004-048417 | 2004-02-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/339,790 Continuation US20090203604A1 (en) | 2004-02-24 | 2008-12-19 | Soothing agent and food for treating fatigue |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005079826A1 true WO2005079826A1 (ja) | 2005-09-01 |
Family
ID=34879510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001752 WO2005079826A1 (ja) | 2004-02-24 | 2005-02-07 | 疲労回復剤及び疲労回復用食品 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20080009440A1 (ja) |
EP (1) | EP1721616B1 (ja) |
JP (1) | JP2005239579A (ja) |
DE (1) | DE602005013650D1 (ja) |
WO (1) | WO2005079826A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009221135A (ja) * | 2008-03-14 | 2009-10-01 | Gekkeikan Sake Co Ltd | 疲労軽減剤 |
WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007119590A1 (ja) * | 2006-03-31 | 2007-10-25 | Nisshin Pharma Inc. | 小麦由来の血圧低下用組成物 |
KR20090019813A (ko) * | 2006-06-13 | 2009-02-25 | 메이지 데어리즈 코포레이션 | 아미노산 조성물을 함유하는 피로 방지제 |
CA2901469A1 (en) | 2013-03-08 | 2014-09-12 | Axiom Foods, Inc. | Rice protein supplements |
US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
EP3634155A4 (en) | 2017-05-12 | 2021-02-17 | Axiom Foods Inc. | RICE PRODUCTS AND SYSTEMS AND PROCESSES FOR THEIR PRODUCTION |
WO2021059755A1 (ja) * | 2019-09-26 | 2021-04-01 | 森永乳業株式会社 | 交感神経活性化用組成物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63287462A (ja) * | 1987-05-21 | 1988-11-24 | Fuji Oil Co Ltd | ペプチド栄養剤 |
JPH01269456A (ja) * | 1988-04-20 | 1989-10-26 | Fuji Oil Co Ltd | スポーツ用食品 |
JPH05505524A (ja) * | 1990-03-09 | 1993-08-19 | ノボ ノルディスク アクティーゼルスカブ | タンパク質加水分解物 |
JPH08264A (ja) * | 1994-04-21 | 1996-01-09 | Ajinomoto Co Inc | 新規チオールプロテアーゼ |
JP2000083695A (ja) * | 1998-09-16 | 2000-03-28 | Ajinomoto Co Inc | 低苦味ペプチドの製造法 |
-
2004
- 2004-02-24 JP JP2004048417A patent/JP2005239579A/ja active Pending
-
2005
- 2005-02-07 EP EP05709804A patent/EP1721616B1/en not_active Expired - Fee Related
- 2005-02-07 DE DE602005013650T patent/DE602005013650D1/de active Active
- 2005-02-07 US US10/589,073 patent/US20080009440A1/en not_active Abandoned
- 2005-02-07 WO PCT/JP2005/001752 patent/WO2005079826A1/ja active Application Filing
-
2008
- 2008-12-19 US US12/339,790 patent/US20090203604A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63287462A (ja) * | 1987-05-21 | 1988-11-24 | Fuji Oil Co Ltd | ペプチド栄養剤 |
JPH01269456A (ja) * | 1988-04-20 | 1989-10-26 | Fuji Oil Co Ltd | スポーツ用食品 |
JPH05505524A (ja) * | 1990-03-09 | 1993-08-19 | ノボ ノルディスク アクティーゼルスカブ | タンパク質加水分解物 |
JPH08264A (ja) * | 1994-04-21 | 1996-01-09 | Ajinomoto Co Inc | 新規チオールプロテアーゼ |
JP2000083695A (ja) * | 1998-09-16 | 2000-03-28 | Ajinomoto Co Inc | 低苦味ペプチドの製造法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1721616A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009221135A (ja) * | 2008-03-14 | 2009-10-01 | Gekkeikan Sake Co Ltd | 疲労軽減剤 |
WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
Also Published As
Publication number | Publication date |
---|---|
EP1721616B1 (en) | 2009-04-01 |
US20090203604A1 (en) | 2009-08-13 |
US20080009440A1 (en) | 2008-01-10 |
DE602005013650D1 (de) | 2009-05-14 |
JP2005239579A (ja) | 2005-09-08 |
EP1721616A4 (en) | 2008-02-20 |
EP1721616A1 (en) | 2006-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aguirre et al. | Enzymatic hydrolysis of soybean protein using lactic acid bacteria | |
Kaur et al. | Recently isolated food-derived antihypertensive hydrolysates and peptides: A review | |
Chalé et al. | ACE inhibitory, hypotensive and antioxidant peptide fractions from Mucuna pruriens proteins | |
JP4376180B2 (ja) | トリペプチドに富むタンパク水解物 | |
WO2005079826A1 (ja) | 疲労回復剤及び疲労回復用食品 | |
Toopcham et al. | Characterization and identification of angiotensin I-converting enzyme (ACE) inhibitory peptides derived from tilapia using Virgibacillus halodenitrificans SK1-3-7 proteinases | |
Zheng et al. | A novel antioxidative peptide derived from chicken blood corpuscle hydrolysate | |
Segura Campos et al. | Angiotensin I‐converting enzyme inhibitory peptides of chia (Salvia hispanica) produced by enzymatic hydrolysis | |
US20050148504A1 (en) | Cysteine protease inhibitor | |
JPH05505524A (ja) | タンパク質加水分解物 | |
WO1996011584A1 (fr) | Melange de peptides et leurs produits_________________ | |
KR20100057630A (ko) | 아미노산 및 펩티드 제품 | |
WO2011108692A1 (ja) | 筋肉萎縮防止剤 | |
WO2012075570A1 (en) | Bioactive peptides and proteins containing bioactive peptides, their uses and processes for making the same | |
WO2010073531A1 (ja) | 筋肉増強剤 | |
EP4305968A1 (en) | Protein degradation product production method and enzyme preparation | |
Jang et al. | γ-Aminobutyric acid (GABA) production and angiotensin-I converting enzyme (ACE) inhibitory activity of fermented soybean containing sea tangle by the co-culture of Lactobacillus brevis with Aspergillus oryzae | |
JPH05236909A (ja) | グルタミン含量の高いペプチド組成物、その製造方法及び経腸栄養剤 | |
US20100286034A1 (en) | Uses for aqueous streams containing proteins | |
US10842164B2 (en) | Composition containing amino acids and process for producing same | |
JP2017521498A (ja) | 植物のオリゴペプチドの単離およびその使用 | |
WO2022168413A1 (ja) | デプレスタチン含有組成物の製造方法 | |
EP3197288A1 (en) | Isolation of plant oligopeptides and uses thereof | |
CN111423489B (zh) | 抗氧化肽、含有该抗氧化肽的大豆蛋白水解物 | |
Savoy de Giori et al. | An overview of lactic acid bacteria applications for healthful soy foods development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005709804 Country of ref document: EP Ref document number: 10589073 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005709804 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10589073 Country of ref document: US |